Eirik Joakim Tranvåg's picture

Eirik Joakim Tranvåg

Assistant Professor
Medisinsk fakultet, fellesfunksjon
  • E-mailEirik.Tranvag@uib.no
  • Phone+47 55 58 61 31+47 918 84 444
  • Visitor Address
    Årstadveien 21
    5009 Bergen
  • Postal Address
    Postboks 7804

PhD project: priority setting for new and expensive cancer drugs - seeking new roles for age and biomarkers in clinical decision making. 

Colaboration between Bergen Centre for Ethics and Priority Setting and Centre for Cancer Biomarkers.

General research interests:

Priority setting in health care

Age and priority setting

Health inequalities, measures of health inequality

Global health

Medical ethics

Academic article
  • Show author(s) 2018. Clinical decision making in cancer care: a review of current and future roles of patient age. BMC Cancer. 7 pages.
  • Show author(s) 2013. Health inequalities in Ethiopia: modeling inequalities in length of life within and between population groups. International Journal for Equity in Health. 8 pages.
  • Show author(s) 2019. Organ donation with the use of normothermic regional perfusion in patients who die after cardiac and respiratory arrest after withdrawal of life-sustaining treatment. .
Reader opinion piece
  • Show author(s) 2018. Er protonterapi riktig bruk av sparsomme ressurser? Tidsskrift for Den norske legeforening. 1504-1505.
  • Show author(s) 2016. E.J. Tranvåg & K.H. Onarheim svarer. Tidsskrift for Den norske legeforening. 204-204.
Academic anthology/Conference proceedings
  • Show author(s) 2017. Cancer Biomarkers: Ethics, Economics and Society. Megaloceros Press.
Popular scientific article
  • Show author(s) 2016. Den brutale arven etter Ebola. Aftenposten Viten.
Feature article
  • Show author(s) 2019. Konfidensielle legemiddelpriser undergraver tilliten til systemet. Tidsskrift for Den norske legeforening. 2 pages.
  • Show author(s) 2015. Ebola er ikke Sierra Leones største problem. Tidsskrift for Den norske legeforening.
  • Show author(s) 2020. Prioriteringer av helseressurser. 169-178. In:
    • Show author(s) 2020. Etikk i helsetjenesten. Gyldendal Akademisk.

More information in national current research information system (CRIStin)

Tranvåg EJ, Norheim OF, Ottersen T. Clinical decision making in cancer care: a review of current and future roles of patient age. BMC Cancer. 2018 Dec 1;18(1):546.

Tranvåg EJ, Norheim OF. How can biomarkers influence priority setting for cancer drugs? Chapter in Cancer biomarkers: ethics, economics and society. Eds. Blanchard A & Strand R. Megaloceros press 2017.

Tranvåg EJ, Onarheim KH. Ebola er ikke Sierra Leones største problem. Tidsskriftet for den Norske Legeforening 2015; 135:2192 – 3

Tranvåg EJ, Nygaard E, Norheim OF. Hvordan påvirker prioriteringsvilkårene rettighetstildelingen i Helsedirektoratets prioriteringsveiledere? Michael 2015; 12: 416–27.

Tranvåg EJ, Ali M, Norheim OF. Health inequalities in Ethiopia: modeling inequalities in length of life within and between population groups. Int J Equity Health. 2013;12:52

Opinion pieces (in norwegian)

Tranvåg EJ
Konfidensielle legemiddelpriser undergraver tillitten til systemet Tidsskrift for den norske legeforening 13.mai 2019

Tranvåg EJ
Åpent? Nei! Rettferdig? Hvem vet? Dagens Medisin 21.03.2019

Tranvåg EJ
Er protonterapi riktig bruk av sparsomme ressurser? Tidsskrift for den norske legeforening 15.10.2018

Tranvåg EJ, Emberland KE
Var det straffe? Var det offside? Morgenbladet 08.07.2018

Tranvåg EJ
Åpenhet om legemidler fremmer dialog Dagens Medisin 08.04.2018

Tranvåg EJ
E-helse er ikke svaret Dagens Medisin 25.04.2017

Tranvåg EJ, Onarheim KH
Inkonsekvent om hemmelighold Dagens Medisin 16.03.2017

Onarheim KH, Tranvåg EJ
Udemokratisk hemmelighold NRK Ytring 27.01.2017

Tranvåg EJ
Protoner, politikk og prioriteringer Dagens Medisin 26.08.2016

Tranvåg EJ
Debatten om kreftmedisiner krever korrekte fakta Aftenposten 19.08.2017

Tranvåg EJ
Helsestasjonisme og helseprioriteringer Morgenbladet 12.08.2016

Haaskjold Y, Tranvåg EJ
Den brutal arven etter ebola Aftenposten 11.04.2016

The new era of personalized cancer diagnostics and therapy: seeking new roles for age and biomarkers in clinical decision making

This PhD project is uniquely positioned at the intersection between medical ethics, priority setting, and biomedical and clinical cancer research, and will engage into one of modern medicines most controversial and polemic issues: setting priorities for new precision medicines for advanced and incurable cancer. Precision medicines and targeted therapy for cancer have showed great promise, but have also created new challenges for priority setting in health. Two important personal characteristics are patient age and expression of potential biomarkers, and to utilize such features when tailoring treatment for individual patients can increase benefit and reduce side effects.

However, little is known about how clinical decision-makers actually perceive and use such individual patient characteristics when allocating new and expensive cancer drugs. Our project seeks to fill this gap and the potential benefit is large: At a clinical level, proper use of age and biomarkers in the decision making process will help tailor treatment for each individual patient and it will also assist physicians in their daily clinical work. At an administrative level, our findings will guide and inform the priority setting process at hospitals and among health authorities. At a national level, the work in this project will link naturally up to some of the Norwegian health systems biggest challenges and public debates.

Cand.med., Faculty of Medicine and Dentistry,University of Bergen, Norway, 2005 - 2011